



Cryolife Files Form 10-Q For First Quarter 2004

May 13, 2004

ATLANTA, May 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a bio-surgical device and human tissue processing company, announced today that it has addressed with the Securities and Exchange Commission ("SEC") its accounting for product liability claims and filed its Form 10-Q for the first quarter.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SG Model #100 Vascular Graft, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: <http://www.cryolife.com>

Contact: D. Ashley Lee
Vice President and CFO
(770) 419-3355

SOURCE CryoLife, Inc.

D. Ashley Lee, Vice President and CFO of CryoLife, Inc.,
+1-770-419-3355

<http://www.cryolife.com>